Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

918 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of Delayed Addition of Anti-EGFR Monoclonal Antibodies on the Outcome of First-Line Therapy in Metastatic Colorectal Cancer Patients: a Retrospective Registry-Based Analysis.
Fiala O, Veskrnova V, Chloupkova R, Poprach A, Kiss I, Kopeckova K, Dusek L, Slavicek L, Kohoutek M, Finek J, Svoboda M, Petruzelka L, Boubliková L, Dvorak J, Melichar B, Buchler T. Fiala O, et al. Among authors: kiss i. Target Oncol. 2018 Dec;13(6):735-743. doi: 10.1007/s11523-018-0597-7. Target Oncol. 2018. PMID: 30353488
Regorafenib for Metastatic Colorectal Cancer: An Analysis of a Registry-Based Cohort of 555 Patients.
Novakova-Jiresova A, Kopeckova K, Boublikova L, Chloupkova R, Melichar B, Petruzelka L, Finek J, Fiala O, Grell P, Batko S, Linke Z, Kiss I, Prausova J, Buchler T. Novakova-Jiresova A, et al. Among authors: kiss i. Cancer Manag Res. 2020 Jul 3;12:5365-5372. doi: 10.2147/CMAR.S255332. eCollection 2020. Cancer Manag Res. 2020. PMID: 32753954 Free PMC article.
Regorafenib in the Real-Life Clinical Practice: Data from the Czech Registry.
Kopeckova K, Buchler T, Bortlicek Z, Hejduk K, Chloupkova R, Melichar B, Pokorna P, Tomasek J, Linke Z, Petruzelka L, Kiss I, Prausova J. Kopeckova K, et al. Among authors: kiss i. Target Oncol. 2017 Feb;12(1):89-95. doi: 10.1007/s11523-016-0458-1. Target Oncol. 2017. PMID: 27638381
Tyrosine kinase inhibitors in the first-line treatment for metastatic nonclear cell renal carcinoma: A retrospective analysis of a national database.
Poprach A, Rumanova K, Lakomý R, Chloupková R, Stanik M, Pokrivcak T, Kiss I, Slaby O, Studentova H, Melichar B, Juracek J, Fiala O, Kopecky J, Kopeckova K, Zemanova M, Buchler T. Poprach A, et al. Among authors: kiss i. Urol Oncol. 2019 Apr;37(4):294.e1-294.e8. doi: 10.1016/j.urolonc.2018.12.017. Epub 2019 Jan 23. Urol Oncol. 2019. PMID: 30683455
Clinical and laboratory prognostic factors in patients with metastatic renal cell carcinoma treated with sunitinib and sorafenib after progression on cytokines.
Poprach A, Pavlik T, Melichar B, Kubackova K, Bortlicek Z, Svoboda M, Lakomy R, Vyzula R, Kiss I, Dusek L, Buchler T; Czech Renal Cancer Cooperative Group. Poprach A, et al. Among authors: kiss i. Urol Oncol. 2014 May;32(4):488-95. doi: 10.1016/j.urolonc.2013.09.011. Epub 2013 Dec 8. Urol Oncol. 2014. PMID: 24321257
918 results